{"disease":{"id":"pediatric-aml","name":"pediatric aml"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06211452","title":"Comparison of Consolidation Strategies for Pediatric Patients With Acute Myeloid Leukemia","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":258,"lead_sponsor_name":"Grupo Argentino de Tratamiento de la Leucemia Aguda","has_results":false},{"nct_id":"NCT03455140","title":"A Study Evaluating the Safety and Activity of Pegylated Recombinant Human Arginase (BCT-100)","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":49,"lead_sponsor_name":"University of Birmingham","has_results":false},{"nct_id":"NCT05313958","title":"Treateament of Newly Diagnosed Acute Monocytic Leukemia in Children","phase":"PHASE2, PHASE3","overall_status":"UNKNOWN","enrollment_count":43,"lead_sponsor_name":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","has_results":false},{"nct_id":"NCT04033627","title":"TCDαβ/CD45RA Haploidentical Transplantation in Children With Leukemia","phase":"NA","overall_status":"UNKNOWN","enrollment_count":30,"lead_sponsor_name":"Shanghai Children's Medical Center","has_results":false},{"nct_id":"NCT01177540","title":"Efficacy and Safety of Decitabine as Epigenetic Priming With Induction Chemotherapy in Pediatric Acute Myelogenous Leukemia (AML) Subjects","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":25,"lead_sponsor_name":"Eisai Inc.","has_results":true},{"nct_id":"NCT07156435","title":"Vyxeos® With Clofarabine for Pediatric AML","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":25,"lead_sponsor_name":"Princess Maxima Center for Pediatric Oncology","has_results":false},{"nct_id":"NCT04562792","title":"Low Dose Daunorubicin in Pediatric Relapsed/Refractory Acute Leukemia","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":1,"lead_sponsor_name":"Children's Mercy Hospital Kansas City","has_results":true},{"nct_id":"NCT05622591","title":"ELU001 in Pediatric Subjects Who Have Relapsed and/or Refractory CBFA2T3-GLIS2-positive AML","phase":"PHASE1","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Elucida Oncology","has_results":false},{"nct_id":"NCT03245424","title":"Ivosidenib Expanded Access Program in Relapsed/Refractory AML With an IDH1 Mutation","phase":"","overall_status":"APPROVED_FOR_MARKETING","enrollment_count":null,"lead_sponsor_name":"Agios Pharmaceuticals, Inc.","has_results":false}],"total":9},"guidelines":[],"source":"Drug Landscape verified database"}